Insulin Glargine Has No Peak Effect
Insulin glargine does not have a peak effect—it provides a relatively constant, peakless insulin level over approximately 24 hours. This fundamental pharmacodynamic property distinguishes it from intermediate-acting insulins like NPH and is the primary reason for its reduced hypoglycemia risk, particularly during nocturnal hours.
Pharmacodynamic Profile
The defining characteristic of insulin glargine is its peakless action profile. After subcutaneous injection, glargine forms microprecipitates in the neutral pH of subcutaneous tissue, from which insulin is gradually and continuously released 1. This results in:
The FDA label explicitly states that glargine provides "a relatively constant concentration/time profile over 24 hours with no pronounced peak in comparison to NPH insulin" 1. Clinical glucose clamp studies demonstrate that the median duration of pharmacological effect extends to 24 hours (range: 10.8 to >24 hours), compared to only 14.5 hours for NPH insulin 1.
Clinical Implications
This peakless profile translates directly into reduced hypoglycemia risk, especially nocturnally. In patients with type 1 diabetes, symptomatic hypoglycemia occurred in 39.9% of glargine users versus 49.2% with NPH insulin (P = 0.02) 2. The absence of a peak means:
- More physiologic basal insulin replacement that mimics endogenous pancreatic secretion 2
- Once-daily dosing is sufficient for 24-hour coverage 2, 3
- Reduced need for timed meals to match insulin peaks, unlike NPH which requires eating at set intervals 2
- Greater flexibility in injection timing without compromising glycemic control 4
Contrast with Other Insulins
Understanding glargine's profile requires comparison:
- NPH insulin: Peaks at 4-10 hours, requiring meal timing to prevent hypoglycemia 3
- Regular insulin: Peaks at 2-3 hours 3
- Rapid-acting analogs: Peak at 1-2 hours 3
- Glargine: No peak, constant effect 3
Important Caveats
While glargine is marketed as "peakless," individual variability exists. The FDA label notes that "the time course of action of insulins, including Insulin Glargine, may vary between patients and within the same patient" 1. Some patients may experience:
- Duration less than 24 hours in certain individuals, occasionally requiring twice-daily dosing 4
- Slight variations in absorption based on injection site (abdomen, deltoid, thigh), though these are not clinically significant 1
- U-300 glargine formulation provides even more prolonged, flatter action than U-100 glargine 5, 6
The absence of a peak is glargine's defining therapeutic advantage, enabling safer basal insulin replacement with reduced hypoglycemia burden compared to traditional intermediate-acting insulins.